Nuclear Medicine Market – By Product, By Application, By End Use - Global Forecast, 2024 – 2032

Report ID: GMI12229
   |
Published Date: November 2024
 | 
Report Format: PDF

Download Free PDF

Nuclear Medicine Market Size

The global nuclear medicine market was valued at around USD 13.6 billion in 2023 and is expected to exhibit growth at a CAGR of 16.3% from 2025 to 2034. Increase in growth can be attributed to the increasing prevalence of cancer and cardiovascular diseases, growing population, and the demand for non-invasive diagnostic techniques and development of new radiopharmaceuticals, among others.
 

Nuclear Medicine Market

Nuclear medicine has increased wider acceptance for use in therapeutic applications, and it’s extensively utilized in oncology. Theranostics is a developing field that involves the use of radiopharmaceuticals such as Lutetium-177 and Actinium-225, which are targeted at specific tumors to treat cancers. The application of these two drugs is increasing for personalized treatments of some types of prostate and neuroendocrine tumors.
 

In addition, investments by governments and other research organizations into the development of nuclear medicine are phenomenal for health infrastructure, increasing availability for advanced diagnostic procedures, and improving the general health of populations. One of the country’s programs, particularly in developed nations, allocates money to purchase advanced diagnostic equipment and build radiopharmacy facilities.
 

For example, the Society of Nuclear Medicine and Molecular Imaging (SNMMI) promotes nuclear medicine and radiopharmaceutical therapies through its value initiative, which is a comprehensive plan for the engagement of all industry stakeholders to promote use and accessibility for patients. In addition to that, there is a noted preference of patients and healthcare providers alike for non-intrusive methods of diagnostics as it poses minimal risk and discomfort. Even though PET and SPECT are modes of nuclear medicine, they are a bit less invasive when comparing them to some conventional forms of diagnosis. This variation in diagnosis supports the growth of the market.
 

Nuclear medicine is a branch of medicine concerned with the utilization of radioactive substances in diagnostic and therapeutic procedures. A small trace of radiopharmaceuticals is injected into the body, and a SYMPTOMATIC scan or an MRI is undertaken for imaging purposes to find out how the body is functioning in real-time. This enables early detection of diseases and provides treatment options that are best suited for the patient. It is especially effective in the treatment of cancer and heart ailments.

 

Authors: Mariam Faizullabhoy, Gauri Wani
Frequently Asked Question(FAQ) :
Who are some of the prominent players in the nuclear medicine industry?
Key players in the industry include Actinium Pharmaceuticals, Boston Scientific, Bracco, Cardinal Health, Curium Pharma, GE Healthcare, Jubilant Pharma, Lantheus, Novartis, RadioMedix, RLS Radiopharmacies, Siemens Healthineers, and Sirtex.
What is the size of the diagnostics segment in the nuclear medicine industry?
How much is the North America nuclear medicine industry worth?
How big is the nuclear medicine market?
Nuclear Medicine Market Scope
  • Nuclear Medicine Market Size
  • Nuclear Medicine Market Trends
  • Nuclear Medicine Market Analysis
  • Nuclear Medicine Market Share
Related Reports
    Authors: Mariam Faizullabhoy, Gauri Wani
    Buy Now
    $4,123 $4,850
    15% off
    $4,840 $6,050
    20% off
    $5,845 $8,350
    30% off
        Buy now
    Premium Report Details

    Base Year: 2023

    Companies covered: 15

    Tables & Figures: 310

    Countries covered: 20

    Pages: 130

    Download Free PDF

    Top